Base de dados : MEDLINE
Pesquisa : C23.550.470.646 [Categoria DeCS]
Referências encontradas : 322 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 33 ir para página                         

  1 / 322 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28722107
[Au] Autor:Capobianco A; Cottone L; Monno A; Manfredi AA; Rovere-Querini P
[Ad] Endereço:San Raffaele Scientific Institute, Division of Immunology, Transplantation, and Infectious Diseases, Milan, Italy.
[Ti] Título:The peritoneum: healing, immunity, and diseases.
[So] Source:J Pathol;243(2):137-147, 2017 Oct.
[Is] ISSN:1096-9896
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The peritoneum defines a confined microenvironment, which is stable under normal conditions, but is exposed to the damaging effect of infections, surgical injuries, and other neoplastic and non-neoplastic events. Its response to damage includes the recruitment, proliferation, and activation of a variety of haematopoietic and stromal cells. In physiological conditions, effective responses to injuries are organized; inflammatory triggers are eliminated; inflammation quickly abates; and the normal tissue architecture is restored. However, if inflammatory triggers are not cleared, fibrosis or scarring occurs and impaired tissue function ultimately leads to organ failure. Autoimmune serositis is characterized by the persistence of self-antigens and a relapsing clinical pattern. Peritoneal carcinomatosis and endometriosis are characterized by the persistence of cancer cells or ectopic endometrial cells in the peritoneal cavity. Some of the molecular signals orchestrating the recruitment of inflammatory cells in the peritoneum have been identified in the last few years. Alternative activation of peritoneal macrophages was shown to guide angiogenesis and fibrosis, and could represent a novel target for molecular intervention. This review summarizes current knowledge of the alterations to the immune response in the peritoneal environment, highlighting the ambiguous role played by persistently activated reparative macrophages in the pathogenesis of common human diseases. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Doenças Peritoneais/fisiopatologia
Peritônio/fisiologia
[Mh] Termos MeSH secundário: Doenças Autoimunes/etiologia
Endometriose/etiologia
Endometriose/imunologia
Endometriose/fisiopatologia
Feminino
Seres Humanos
Imunidade Celular/fisiologia
Doenças Peritoneais/etiologia
Doenças Peritoneais/imunologia
Fibrose Peritoneal/etiologia
Fibrose Peritoneal/imunologia
Fibrose Peritoneal/fisiopatologia
Neoplasias Peritoneais/etiologia
Neoplasias Peritoneais/imunologia
Neoplasias Peritoneais/fisiopatologia
Peritônio/anatomia & histologia
Peritônio/imunologia
Peritonite/etiologia
Peritonite/patologia
Peritonite/fisiopatologia
Serosite/etiologia
Cicatrização/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE
[do] DOI:10.1002/path.4942


  2 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28240590
[Au] Autor:Nevskaya T; Gamble MP; Pope JE
[Ad] Endereço:Division of Rheumatology, Department of Medicine, Joseph's Health Care, London, Canada.
[Ti] Título:A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors.
[So] Source:Clin Exp Rheumatol;35(4):700-710, 2017 Jul-Aug.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the prevalence of and risk factors for avascular necrosis (AVN) in systemic lupus erythematosus (SLE). METHODS: MEDLINE, CINAHL, Web of Science, EMBASE and Cochrane Library were searched from inception to July, 2015 and a random effects model was used to combine frequencies; study quality was assessed using STROBE. RESULTS: 2,041 citations identified 62 articles. Many results had high heterogeneity. The prevalence of symptomatic AVN was 9% (range 0.8%-33%) in SLE and 29% for asymptomatic AVN; femoral head was the most common location (8.0%). High-dose corticosteroids (CS) any CS use, maximum and cumulative dose, pulse therapy, and CS side-effects (hypertension, Cushings, but not diabetes mellitus or hyperlipidaemia) were associated with AVN, as was active SLE (cutaneous vasculitis, renal and neuropsychiatric manifestations, serositis, cytopenias) and Sjögren's, Raynaud's phenomenon, arthritis, cyclophosphamide (but not azathioprine mycophenolate mofetil, or methotrexate) and more damage (excluding musculoskeletal system). Antimalarial drugs were not protective. Rashes and oral ulcers were not associated with AVN. Mean daily dose of CS and duration of CS use had no impact on AVN occurence. Autoantibodies and other immunological markers did not predispose to AVN, except IgM anticardiolipin antibodies which doubled the risk. African Americans experienced more AVN (OR 1.8, p=0.04). CONCLUSIONS: AVN may occur in 1/3 of patients with SLE and 9% with symptoms. Features of active organ SLE (CNS, renal, cutaneous vasculitis, serositis, cytopenias) are associated with AVN as are CS, especially early in disease and at high doses. Those with early CS side-effects seem to have the highest risk of AVN.
[Mh] Termos MeSH primário: Lúpus Eritematoso Sistêmico/epidemiologia
Osteonecrose/epidemiologia
[Mh] Termos MeSH secundário: Corticosteroides/administração & dosagem
Corticosteroides/efeitos adversos
Corticosteroides/uso terapêutico
Síndrome de Cushing/induzido quimicamente
Síndrome de Cushing/epidemiologia
Necrose da Cabeça do Fêmur/epidemiologia
Seres Humanos
Hipertensão/induzido quimicamente
Hipertensão/epidemiologia
Lúpus Eritematoso Sistêmico/tratamento farmacológico
Nefrite Lúpica/epidemiologia
Vasculite Associada ao Lúpus do Sistema Nervoso Central/epidemiologia
Prevalência
Fatores de Risco
Serosite/epidemiologia
Dermatopatias/epidemiologia
Vasculite/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170228
[St] Status:MEDLINE


  3 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28137906
[Au] Autor:Kirpalani A; Rieder MJ; Bax KC; Filler G
[Ad] Endereço:Department of Paediatrics, University of Western Ontario, London, Ontario, Canada.
[Ti] Título:Idiosyncratic drug reactions and membranous glomerulopathy.
[So] Source:BMJ Case Rep;2017, 2017 Jan 30.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:An infant boy with steroid-resistant nephrotic syndrome (idiopathic membranous glomerulonephropathy) achieved remission with ciclosporin but developed eosinophilia and high IgE levels (max 19 000  iU/mL). Conversion to tacrolimus resulted in chronic diarrhoea (eosinophilic gastroenteritis), muscle weakness, polyserositis and failure-to-thrive. In contrast, a trial without tacrolimus resulted in a ciclosporin-responsive relapse, therapy-resistant focal seizures with generalised spikes, worsening muscle weakness and diarrhoea. The patient was weaned off of ciclosporin and completely normalised. In vitro testing demonstrated decreased viability of the patient's cells when incubated with calcineurin inhibitors (ciclosporin, 70%; tacrolimus, 80% compared to control cells), supporting their role in this adverse drug reaction.
[Mh] Termos MeSH primário: Ciclosporina/efeitos adversos
Enterite/induzido quimicamente
Eosinofilia/induzido quimicamente
Gastrite/induzido quimicamente
Glomerulonefrite Membranosa/tratamento farmacológico
Imunossupressores/efeitos adversos
Convulsões/induzido quimicamente
Tacrolimo/efeitos adversos
Vasculite/induzido quimicamente
[Mh] Termos MeSH secundário: Sobrevivência Celular
Desprescrições
Substituição de Medicamentos
Insuficiência de Crescimento/induzido quimicamente
Hiperplasia Gengival/induzido quimicamente
Glomerulonefrite Membranosa/diagnóstico
Glomerulonefrite Membranosa/patologia
Seres Humanos
Hipertricose/induzido quimicamente
Técnicas In Vitro
Lactente
Glomérulos Renais/ultraestrutura
Masculino
Microscopia Eletrônica
Debilidade Muscular/induzido quimicamente
Serosite/induzido quimicamente
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 83HN0GTJ6D (Cyclosporine); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170201
[St] Status:MEDLINE


  4 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28104132
[Au] Autor:Kim K; Jeong DW; Lee YH; Kim YG; Moon JY; Jeong KH; Lee TW; Ihm CG; Joo SH; Park HC; Lee SH
[Ad] Endereço:Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
[Ti] Título:Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report.
[So] Source:Transplant Proc;49(1):181-184, 2017 Jan - Feb.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although everolimus, a mammalian target of rapamycin inhibitor, has been used as a potent immunosuppressive agent in organ transplantation, data regarding its adverse effect profile compared with that of sirolimus in clinical circumstances are limited. A 50-year-old man who underwent simultaneous liver and kidney transplantation 14 months previously was admitted with large pleural effusion, pericardial effusion, and ascites. Laboratory findings and cultures for possible infectious causes were all negative. Pericardial window surgery with drainage of the pericardial fluid was performed on day 3. Pleural and pericardial biopsy revealed non-specific inflammation without evidence of malignant cells. Everolimus was discontinued and replaced by mycophenolate mofetil on day 4. Significant clinical improvement was observed after discontinuation of everolimus, and follow-up echocardiography and chest radiography showed no recurrence of the pericardial or pleural effusion after discharge.
[Mh] Termos MeSH primário: Everolimo/efeitos adversos
Rejeição de Enxerto/prevenção & controle
Imunossupressores/efeitos adversos
Transplante de Rim
Transplante de Fígado
Derrame Pericárdico/induzido quimicamente
Derrame Pleural/induzido quimicamente
Serosite/induzido quimicamente
[Mh] Termos MeSH secundário: Ascite/induzido quimicamente
Nefropatias Diabéticas/complicações
Drenagem
Ecocardiografia
Seres Humanos
Imunossupressores/uso terapêutico
Falência Renal Crônica/etiologia
Falência Renal Crônica/cirurgia
Cirrose Hepática Alcoólica/cirurgia
Masculino
Meia-Idade
Derrame Pericárdico/diagnóstico por imagem
Pericardite/induzido quimicamente
Pericardite/diagnóstico por imagem
Pericardite/patologia
Derrame Pleural/diagnóstico por imagem
Pleurisia/induzido quimicamente
Pleurisia/diagnóstico por imagem
Pleurisia/patologia
Prednisolona/uso terapêutico
Serosite/diagnóstico por imagem
Serosite/patologia
Tacrolimo/uso terapêutico
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 9HW64Q8G6G (Everolimus); 9PHQ9Y1OLM (Prednisolone); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE


  5 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27999942
[Au] Autor:Liang Y; Leng RX; Pan HF; Ye DQ
[Ad] Endereço:Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, People's Republic of China.
[Ti] Título:The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study.
[So] Source:Rheumatol Int;37(2):305-311, 2017 Feb.
[Is] ISSN:1437-160X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:This study aims to estimate the prevalence of serositis and identify risk factors for serositis in a large cohort of systemic lupus erythematosus (SLE) patients. A cross-sectional study was conducted based on the medical records of patients hospitalized with SLE at the First Affiliated Hospital of Anhui Medical University and Anhui Provincial Hospital. Patients were diagnosed with serositis when they presented with symptoms and signs of pleuritis or/and pericarditis. We explored factors associated with the generation and quantity of serositis by using binary and ordinal logistic regression analysis. Among the 1668 lupus patients, 298 have serositis. Active lupus disease, fever (≥38 °C) and high D-dimer were all significantly associated with the generation and quantity of serositis. Male gender was independent significant risk factor for pleuritis but not for pericarditis, while low complement C4 and high erythrocyte sedimentation rate (ESR) were risk factors for pericarditis rather than for pleuritis. The possible prevalence of serositis in patients with SLE was 17.9%. The significant associations of active lupus disease, fever (≥38 °C) and high D-dimer with serositis suggest that higher disease activity and hypercoagulability may both contribute to the generation and development of serositis in SLE. The risk factors for pleuritis and pericarditis in SLE are similar but not identical.
[Mh] Termos MeSH primário: Lúpus Eritematoso Sistêmico/complicações
Serosite/epidemiologia
Serosite/etiologia
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo
Seres Humanos
Lúpus Eritematoso Sistêmico/sangue
Masculino
Prevalência
Fatores de Risco
Serosite/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrin Fibrinogen Degradation Products); 0 (fibrin fragment D)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1007/s00296-016-3630-0


  6 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27803306
[Au] Autor:Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
[Ad] Endereço:Department of Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, the Netherlands m.tsangasjoe@vumc.nl.
[Ti] Título:Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
[So] Source:Rheumatology (Oxford);56(1):121-128, 2017 Jan.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To identify predictors of organ damage and specifically the relationship between prolonged disease remission or low disease activity and damage accrual in a longitudinal cohort of SLE patients. METHODS: Data were prospectively assessed including the occurrence of minor/major flares. Once a year remission and Lupus Low Disease Activity State (LLDAS) were determined retrospectively. A prediction model for damage accrual during follow-up was constructed with backward logistic regression analyses. Secondly, odds ratios (ORs) for damage accrual (SLICC damage index increase of ⩾ 1 during follow-up) were calculated for patients with or without prolonged remission during 5 years, and with or without LLDAS in ⩾ 50% of observations. RESULTS: Data from 183 patients with a median follow-up duration of 5.0 years were analysed. The most significant predictors for damage accrual were: occurrence of ⩾ 1 major flare, mean daily prednisone dose during follow-up and nephrological manifestations at baseline. Prolonged remission was present in 32.5% (38/117) and LLDAS in ⩾ 50% of observations in 64.5% (118/183) of patients. Both the presence of prolonged remission during 5 years and LLDAS in ⩾ 50% of observations were associated with a reduced risk of damage accrual (OR = 0.20, 95% CI: 0.07, 0.53, P = 0.001 and OR = 0.52, 95% CI: 0.28, 0.99, P = 0.046, respectively). CONCLUSION: This cohort study shows that prolonged remission and LLDAS were associated with an improved outcome, as determined by yearly assessments. In order to improve the outcome in SLE patients, future studies should investigate whether these targets can be reached actively with therapeutic strategies.
[Mh] Termos MeSH primário: Lúpus Eritematoso Sistêmico/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Artrite/etiologia
Catarata/induzido quimicamente
Estudos de Coortes
Diabetes Mellitus/induzido quimicamente
Progressão da Doença
Feminino
Glucocorticoides/efeitos adversos
Glucocorticoides/uso terapêutico
Seres Humanos
Hipertensão Pulmonar/etiologia
Estudos Longitudinais
Lúpus Eritematoso Sistêmico/complicações
Lúpus Eritematoso Sistêmico/tratamento farmacológico
Nefrite Lúpica/etiologia
Masculino
Meia-Idade
Mielite Transversa/etiologia
Razão de Chances
Osteomielite/etiologia
Osteonecrose/induzido quimicamente
Osteoporose/induzido quimicamente
Fraturas por Osteoporose/induzido quimicamente
Pancreatite/etiologia
Prednisona/efeitos adversos
Prednisona/uso terapêutico
Estudos Prospectivos
Indução de Remissão
Estudos Retrospectivos
Serosite/etiologia
Índice de Gravidade de Doença
Dermatopatias/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170620
[Lr] Data última revisão:
170620
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161103
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kew377


  7 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27357280
[Au] Autor:Jose A; Cramer AK; Davar K; Gutierrez G
[Ad] Endereço:Pulmonary, Critical Care and Sleep Medicine Division, The George Washington University, Washington, DC, USA.
[Ti] Título:A case of drug-induced lupus erythematosus secondary to trimethoprim/sulfamethoxazole presenting with pleural effusions and pericardial tamponade.
[So] Source:Lupus;26(3):316-319, 2017 Mar.
[Is] ISSN:1477-0962
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We report a case of drug-induced lupus erythematosus (DILE) secondary to trimethoprim/sulfamethoxazole (TMP/SMX) in a patient with underlying inflammatory bowel disease (IBD). The initial presentation was with febrile pleural and pericardial effusions followed by cardiac tamponade. The patient was treated with a short course of corticosteroids with complete resolution of symptoms. To our knowledge this is the first reported case of TMP/SMX-induced DILE presenting with life-threatening serositis. When confronted with sterile exudative effusions, clinicians should strongly consider non-infectious etiologies.
[Mh] Termos MeSH primário: Corticosteroides/uso terapêutico
Tamponamento Cardíaco/diagnóstico por imagem
Lúpus Eritematoso Sistêmico/complicações
Derrame Pleural/diagnóstico por imagem
Serosite/tratamento farmacológico
Combinação Trimetoprima e Sulfametoxazol/efeitos adversos
[Mh] Termos MeSH secundário: Tamponamento Cardíaco/etiologia
Feminino
Seres Humanos
Doenças Inflamatórias Intestinais/tratamento farmacológico
Lúpus Eritematoso Sistêmico/induzido quimicamente
Meia-Idade
Derrame Pleural/etiologia
Serosite/etiologia
Tomografia Computadorizada por Raios X
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170518
[Lr] Data última revisão:
170518
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160701
[St] Status:MEDLINE
[do] DOI:10.1177/0961203316657435


  8 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27987518
[Au] Autor:Wang L; Yang Y; Jia Y; Miao H; Zhou YS; Zhang XY
[Ad] Endereço:Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
[Ti] Título:[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
[So] Source:Beijing Da Xue Xue Bao Yi Xue Ban;48(6):1081-1085, 2016 12 18.
[Is] ISSN:1671-167X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE). To investigate clinical and laboratory features of SLE-associated episcleritis and scleritis, we now report 4 cases of inpatients who were diagnosed with episcleritis or scleritis secondary to SLE from September 2005 to July 2016 in the Department of Rheumatology and Immunology in Peking University People's Hospital. Demographic, clinical and laboratory characteristics were summarized together with the treatment regimen and the prognosis; the literature was reviewed. There were 3 female and 1 male patients. The average age was (49.0±23.8) years and the mean duration of SLE at the onset of episcleritis or scleritis was (2.1±1.4) years. In addition to the eye involvement, the patients had mucocutaneous manifestations, serositis, lupus nephritis and interstitial pneumonia simultaneously; in the past, 1 patient experienced arthritis, 2 presented Raynaud's phenomenon, and 2 had hematologic involvement. All the patients had antinuclear antibody (ANA) of high titer. The anti double-stranded DNA (ds-DNA) antibody titers were increased in 2 patients. Three patients had positive anti-nucleosome antibody (ANuA) while the other 1 patient did not test it. The complement levels were decreased in 3 patients. The systemic lupus erythematosus disease activity index (SLEDAI) scores were more than 4 points in all the patients (ranging from 7-16), suggesting active disease. Ocular symptoms included pain, redness of the eye and tears. Ophthalmic examinations revealed 3 cases of episcleritis and 1 case of scleritis. Among the 4 patients, 2 patients experienced ocular complications including decrease in vision and uveitis. All the patients were treated with systemic corticosteroids combined with hydroxycloroquine; 3 patients were treated with immunosuppressants (cyclophosphamide in 2 patients and leflunomide in 1 patient). All of the 4 patients received topical steroid and 1 patient received periocular injection of triamcinolone acetonide; 1 patient received topical nonsteroidal anti-inflammatory drug (NSAID).No recurrence of episcleritis or scleritis was observed during the follow-ups. As a conclusion, scleritis and episcleritis, although uncommon, may occur in patients with autoimmune rheumatic diseases including SLE. The occurrence of episcleritis and scleritis may suggest active disease of SLE. Ocular complications need to be aware of in the patients. Prompt diagnosis and treatment was associated with good visual outcomes in the follow-ups.
[Mh] Termos MeSH primário: Lúpus Eritematoso Sistêmico/complicações
Lúpus Eritematoso Sistêmico/tratamento farmacológico
Esclerite/complicações
Esclerite/tratamento farmacológico
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Adulto
Idoso
Anti-Inflamatórios não Esteroides/uso terapêutico
Anticorpos Antinucleares/sangue
Artrite/complicações
Ciclofosfamida/uso terapêutico
Progressão da Doença
Feminino
Doenças Hematológicas/complicações
Seres Humanos
Isoxazóis/uso terapêutico
Doenças Pulmonares Intersticiais/complicações
Nefrite Lúpica/complicações
Masculino
Meia-Idade
Dor
Prognóstico
Doença de Raynaud/complicações
Recidiva
Serosite/complicações
Resultado do Tratamento
Triancinolona Acetonida/uso terapêutico
Uveíte/etiologia
Transtornos da Visão/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Antibodies, Antinuclear); 0 (Isoxazoles); 8N3DW7272P (Cyclophosphamide); F446C597KA (Triamcinolone Acetonide); G162GK9U4W (leflunomide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161218
[St] Status:MEDLINE


  9 / 322 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27585097
[Au] Autor:Panjeti AR; Nemeth NM; Rissi DR
[Ti] Título:Pathology in Practice.
[So] Source:J Am Vet Med Assoc;249(6):603-5, 2016 Sep 15.
[Is] ISSN:1943-569X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Serosite/veterinária
Infecções Estreptocócicas/veterinária
Streptococcus suis/isolamento & purificação
[Mh] Termos MeSH secundário: Abdome
Animais
Animais Recém-Nascidos
Diagnóstico Diferencial
Dispneia/etiologia
Dispneia/veterinária
Evolução Fatal
Feminino
Serosite/complicações
Serosite/diagnóstico
Serosite/patologia
Infecções Estreptocócicas/complicações
Infecções Estreptocócicas/diagnóstico
Infecções Estreptocócicas/patologia
Suínos
Cavidade Torácica
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160902
[St] Status:MEDLINE
[do] DOI:10.2460/javma.249.6.603


  10 / 322 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27570994
[Au] Autor:Lombardero Pin M; Otero Villalustre C; Nucete Gallego B; Mateos Egido E; García Reina L; Santos Morín L; Díez Del Pino A
[Ad] Endereço:Servicio de Farmacia. Complejo Hospitalario Universitario Insular-Materno Infantil Las Palmas de Gran Canaria (CHUIMI). España.. mlompin@gobiernodecanarias.org.
[Ti] Título:[Poliserositis in a patient with hepatitis C under treatment with new antivirals].
[Ti] Título:Poliserositis en paciente con hepatitis C en tratamiento con los nuevos antivirales..
[So] Source:Farm Hosp;40(5):447-8, 2016 09 01.
[Is] ISSN:0214-753X
[Cp] País de publicação:Spain
[La] Idioma:spa
[Mh] Termos MeSH primário: Antivirais/efeitos adversos
Antivirais/uso terapêutico
Hepatite C/complicações
Hepatite C/tratamento farmacológico
Serosite/etiologia
[Mh] Termos MeSH secundário: Idoso
Combinação de Medicamentos
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Drug Combinations)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160830
[St] Status:MEDLINE
[do] DOI:10.7399/fh.2016.40.5.10475



página 1 de 33 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde